Key Insights

Highlights

Success Rate

86% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

8.3%

3 terminated out of 36 trials

Success Rate

85.7%

-0.8% vs benchmark

Late-Stage Pipeline

17%

6 trials in Phase 3/4

Results Transparency

28%

5 of 18 completed with results

Key Signals

5 with results86% success

Data Visualizations

Phase Distribution

25Total
Not Applicable (12)
P 1 (2)
P 2 (5)
P 3 (3)
P 4 (3)

Trial Status

Completed18
Unknown9
Recruiting4
Terminated3
Not Yet Recruiting2

Trial Success Rate

85.7%

Benchmark: 86.5%

Based on 18 completed trials

Clinical Trials (36)

Showing 20 of 20 trials
NCT06940596Not ApplicableRecruiting

Exclude or Expose in Irritable Bowel Syndrome: What Works for Whom and How?

NCT07222800Phase 3Recruiting

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

NCT07504549Not ApplicableNot Yet RecruitingPrimary

Implementation of a Pediatric ERAS-based Protocol in Intestinal Resection With Primary Anastomosis

NCT07351071Not ApplicableRecruiting

Post-Market Study of the Signia Circular Stapler With Tri-Staple Technology in Left-sided Colon, Sigmoid, and Rectal Resections

NCT07366151Not Yet Recruiting

Long-term Health Outcomes of Screen Detected and Potential Celiac Disease Patients

NCT06872151Phase 4Completed

Evaluation of the Effectiveness of a Topical Medical Device in Wound Healing and Symptom Relief in the Postoperative Period of Open Excisional Hemorrhoidectomy (The Emor Study)

NCT06201559Phase 1CompletedPrimary

Bioequivalence Study Between Two Albendazole 400 mg Tablets in Healthy Adult Participants Under Fed Conditions

NCT02831556Completed

Point of Care 3D Ultrasound for Various Applications: A Pilot Study

NCT02647866Phase 2Completed

Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis

NCT04644315Phase 2Terminated

A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors

NCT04949282Recruiting

Spanish Series of Patients Treated With the Radionuclide Lutetium177

NCT04080843Phase 2Completed

Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients

NCT05322486Unknown

Palliative Primary Tumor Resection in Minimally Symptomatic Patients With Colorectal Cancer and Synchronous Unresectable Metastases

NCT04102163Terminated

Health-Related Quality of Life in Crohn's Disease Participants With Complex Perianal Fistula Before and After Treatment

NCT04340089UnknownPrimary

Squatting on the Toilet and Capsule Endoscopy

NCT02227602Not ApplicableCompletedPrimary

Anti-Inflammatory Effects of Mango Polyphenolics in Inflammatory Bowel Disease

NCT02246647CompletedPrimary

Biomarkers for Intestinal Permeability in Patients With Constipation

NCT02005965Unknown

Low Rectal Cancer Study (MERCURY II)

NCT01037049Phase 2Unknown

Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks

NCT01995942Unknown

Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) Trial

Scroll to load more

Research Network

Activity Timeline